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Introduction: Non-alcoholic fatty liver disease (NAFLD) is currently the 
most common form of chronic liver disease. Its prevalence continues to rise, 
and it threatens to become a serious health problem. This study aimed to 
evaluate the diagnostic accuracy of noninvasive fibrosis assessment in 
predicting advanced fibrosis or cirrhosis in patients with NAFLD. 
Methods: One hundred sixteen patients with a liver biopsy-confirmed 
diagnosis of NAFLD were prospectively evaluated between March 2013 and 
September 2014. Liver stiffness measurement (LSM) was performed by 
acoustic radiation force impulse (ARFI) elastography in all patients. Aspartate 
aminotransferase to alanine aminotransferase ratio (AAR), FIB-4 index, 
aspartate aminotransferase to platelet ratio index (APRI), NAFLD fibrosis 
score (NFS) and BARD score were calculated according to published 
algorithms. In order to predict advanced fibrosis or cirrhosis, diagnostic 
measurements of serum fibrosis indices and ARFI imaging were compared by 
analyzing the area under the receiver operating characteristic (AUROC) curve. 
Results: The median age of the study population was 54.3 years (range, 18–
78). The FIB-4 index, NAFLD fibrosis score, BARD score and LSM showed 
significant, positive correlations with the METAVIR stages (P<0.001). The 
LSM by ARFI had the greatest AUROC for predicting advanced fibrosis (≥F3) 
(0.883; 95% CI, 0.804–0.961) and cirrhosis (F4) (0.926; 95% CI, 0.848–




(0.873; 95% CI, 0.803–0.942). 
Conclusions: LSM by ARFI was a useful noninvasive assessment for 
predicting advanced fibrosis and cirrhosis in patients with NAFLD. In 
addition, the FIB-4 index exhibited acceptable diagnostic performance in the 
assessment of hepatic fibrosis in patients with NAFLD. 
---------------------------------------------------------------------------------------------- 
Keywords: Acoustic Radiation Force Impulse, liver stiffness, Non-
alcoholic fatty liver disease, fibrosis 
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Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver 
disease in many parts of the world, especially in developed countries. It has 
been estimated that about one billion individuals worldwide have NAFLD.
1 
The prevalence of NAFLD had been estimated to range between 6.3 and 33%, 
with a median of 20% in the general population.
2 
In Asia, recent reports 
revealed an increasing in the prevalence of NAFLD.
3, 4 
NAFLD is rapidly becoming a major health concern due to the increasing 




The spectrum of NAFLD is diverse, ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH), which can lead to cirrhosis. The 
mainstream management strategy for NAFLD is regular follow-up with risk 
factor modification and early detection of liver fibrosis.
6
 Therefore, the 
prediction of liver fibrosis is very important. 
To date, biopsy has been regarded as the “gold standard” for the diagnosis and 
assessment of liver fibrosis. However, the method is expensive, invasive, and 
has certain limitations. Therefore, biopsy is no longer considered the 
obligatory and primary screening for the diagnosis of NAFLD.
8-12
 
Recently, several liver imaging techniques such as transient elastography 
(TE),
13
 magnetic resonance imaging elastography,
14
 and acoustic radiation 
force impulse (ARFI)
15
 elastography, have been introduced for the assessment 
of hepatic fibrosis.
 




ultrasound-based method integrated into a conventional ultrasound system. 
Furthermore, ARFI enables the exact localization of the elasticity 
measurement site in B-mode, while TE is a blind technique with no B-mode 
imaging for localization. Recently, several studies on ARFI elastography have 
shown promising results on the correlation between hepatic fibrosis and liver 




The aims of this study were to compare the usefulness of the fibrosis indices 
and to evaluate the diagnostic performance of ARFI elastography in predicting 




Materials and Methods 
Study population 
We prospectively evaluated 116 patients with histologically proven NAFLD, 
who were diagnosed by liver biopsy at the Seoul Metropolitan Government 
Seoul National University Boramae Medical Center between March 2013 and 
October 2014. The exclusion criteria included a history of excessive alcohol 
consumption (>20 g daily in women, >30 g daily in men); evidence of 
hepatitis B and C and drug-induced liver disease or other specific liver 
diseases; hemochromatosis; a1-antitrypsin deficiency, Wilson disease; and 
autoimmune liver disease. Because the increased in LS in patients with right-
sided heart failure can result in the misdiagnosis of advanced fibrosis, patients 
with NAFLD and congestive heart failure were also excluded.
19
 None of the 
patients had a clinical history of hepatic decompensation (ascites, bleeding 
from varices, encephalopathy). We included only those patients with 
histologically proven NAFLD. Ascites, varices and encephalopathy indicate 
the presence of cirrhosis, which makes invasive or non-invasive staging of 
fibrosis unnecessary. After excluding patients on the basis of our exclusion 
criteria, 116 patients were prospectively enrolled (NCT02206841). Patients 
with a previous diagnosis of diabetes mellitus or with a fasting glucose level > 
126 mg/dL were defined as diabetic patients. Hypertension was defined as a 
systolic blood pressure >130/85 mmHg or need for treatment. Biochemical 
tests and ARFI elastography were performed on the same day as the liver 




complied with the 1975 Helsinki Declaration. Informed consent was obtained 
from all the study participants who were enrolled in this study. 
 
Liver histology 
Liver biopsy specimens were fixed in 4%-buffered formalin and embedded in 
paraffin. Two-micrometer-thick sections were stained with hematoxylin-eosin 
and Masson trichrome. All biopsy specimens were analyzed by an 
experienced pathologist who was blinded to the clinical results of the patients. 
Histological assessment was performed according to the Kleiner scoring 
system.
20
 Steatosis was assessed according the number of hepatocytes with 
fatty degeneration: S0 = <5%, S1 = 5–33%, S2 = >33–66%, S3 = >66% of 
hepatocytes. Liver fibrosis was staged on a F0–F4 scale according to the 
Kleiner scoring system: F0, no fibrosis; F1, perisinusoidal or periportal 
fibrosis; F2, perisinusoidal and portal or periportal fibrosis; F3, bridging 
fibrosis; and F4, cirrhosis. We excluded patients with biopsy lengths that were 
less than 20 mm, as well as those with biopsies of fewer than eight portal 
tracts. 
 
Serum fibrosis indices 
The clinical and anthropometric data of the study population were collected 
on the same day as liver biopsy. A 12-hour overnight fasting blood sample 
was obtained on the day of liver biopsy to determine the serum levels of 




(AST), gamma-glutamyltranspeptidase (GGT), and total bilirubin, along with 
prothrombin time and platelet count. The formula for calculating the 
homeostasis model assessment of insulin resistance (HOMA-IR) was as 
follows: fasting glucose (mg/dL) × fasting insulin (µU/mL)/405.
21
 The AST-
to-ALT ratio (AAR), and AST-to-platelet ratio index (APRI) were calculated 
as described elsewhere.
22-25
 The FIB-4 index was calculated using the 





The NAFLD fibrosis score (NFS) formula was = –1.675 + 0.037 – age (years) 
+ 0.094 – body mass index (BMI) (kg/m
2
) + 1.13 × impaired fasting glucose 
(IFG)/diabetes (yes = 1, no = 0) + 0.99 × AAR – 0.013 × platelet count (×10
9
/l) 
– 0.66 × albumin (g/dL). Diabetes mellitus was diagnosed when fasting 
glucose level was ≥126 mg/dL or if the patient was treated with anti-diabetic 
drugs, or had IFG (defined as fasting glucose level between 100 and 125 
mg/dL). In each patient with diabetes mellitus or IFG, the level of 
glycosylated hemoglobin (HbA1C) was determined. According to Angulo et 
al, a score lower than –1.455 (low cutoff) excludes advanced fibrosis, whereas 
a score higher than 0.676 (high cutoff) predicts advanced fibrosis. Scores 
between these values are defined as indeterminate.
26
 
The BARD score is composed of the following 3 variables: AAR ≥ 0.8 = 2 
points; BMI ≥ 28 kg/m2 = 1 point; and presence of diabetes = 1 point. The 
possible score ranges from 0 to 4 points. According to the results of Harrison 
et al., BARD scores equaling 0 or 1 are of high (96%) negative predictive 
value (NPV) for advanced fibrosis.
27




compared with the liver biopsy findings. 
 
Acoustic radiation force impulse imaging 
In order to measure of LS, ARFI (Acuson S2000
TM
, Siemens AG, Germany) 
with the Virtual Touch tissue quantification software was used by a single 
experienced radiologist, who was unaware of the clinical and biochemical 
data. Prior to performing ARFI elastography, the gross morphologies of the 
liver, gall bladder, and spleen were examined using conventional 
ultrasonography. With real-time B-mode imaging, a 10 × 5-mm region of 
interest (ROI) cursor was placed on the liver parenchyma at least 3 cm below 
the liver capsule, without any vessel or focal liver lesion. LS measurement 
(LSM) was obtained at the right hepatic lobe, which was accessed through the 
9–10
th
 rib intercostal approach, with the patient in the supine position with the 
right arm in maximum abduction. The mean value of a series of shear wave 
velocities was regarded as LS and expressed in meters per second (m/s). For 
assessing the reproducibility of LSM by mean of ARFI elastography, a 
preliminary study was carried out on 50 patients with chronic liver disease 
who were not included in this study. Consequently, intra-observer 








(interquartile range, IQR). Quantitative data were analyzed using the Student 
t-test or the non-parametric Mann-Whitney U test. Three independent groups 
were compared using one-way analysis of variance (ANOVA). Qualitative 
data were analyzed using the chi-square test. Spearman correlation analysis 
was performed to assess the relationship between the METAVIR stages and 
each fibrosis index. The area under the receiver operating characteristic 
(AUROC) curve was estimated for evaluating ability to classify each 
parameter. Sensitivity (Se), specificity (Sp), positive predictive values (PPVs), 
and negative predictive values (NPVs) were calculated from the AUROC 
curves. Optimal cutoff LS value and serum fibrosis indices were chosen based 
on the highest Youden’s index. The statistical significance of the differences 
between AUROC values was compared using the DeLong’s test. In order to 
measure the inter-observer agreement for the histopathological assessment 
data; the Cohen Kappa statistic was used. Statistical analyses were performed 
using the IBM SPSS Statistics software package version 20.0 (IBM, Inc., 
Chicago, IL, USA) and R version 3.0.2 (http://www.r-project.org). P values < 






Demographic and clinical characteristics of the study 
population 
A total of 116 patients were included in this prospective cohort study. The 
median age was 54.3 years (IQR, 40–65), and 42.2% of the patients were men. 
The median BMI was 26.8 kg/m
2
 (IQR, 24.23–29.98), and the median 
HOMA-IR was 3.61 (IQR, 2.31–5.07). The baseline demographic, clinical, 
and biochemical characteristics of the study population are summarized in 
Table 1. The median value for LS measured by ARFI elastography was 1.13 
m/s (IQR, 0.97–1.35) (Table 1). 
 
Histological characteristics of liver biopsy 
The median length of the biopsy specimens was 2.6 cm (IQR, 2.4–3.0), which 
was compliant with the specimen adequacy criteria. The average number of 
portal tracts of the biopsy specimen was 10 (range 8–24). The distribution of 
the METAVIR stage was as follows: F0 in 5 patients (4.3%), F1 in 56 patients 
(48.3%), F2 in 33 (28.4%), F3 in 10 (8.6%), and F4 in 12 (10.3%). Moderate 
to severe hepatic steatosis (≥33%) was present in 59.4% of the study 







Table 1. Baseline characteristics of the study population 
 Variable Unit Median (IQR) or N (%) 
Sex (male/female) 
 
49 (42.2)/67 (57.8) 
Age years 54.3 (40–65)  
BMI kg/m
2
 26.8 (24.23–29.98) 
Diabetes  44 (37.9) 
Hypertension  50 (43.1) 
Fasting insulin µU/mL 11.9 (8.48–18.3) 
Fasting glucose mg/dL 110 (95–131.75) 
HOMA-IR  3.61 (2.31–5.07) 
Laboratory results   
AST IU/L 37.5 (26–60) 
ALT IU/L 41 (25–62.25) 
GGT IU/L 44.5 (24–82.25) 
Total bilirubin mg/dL 0.8 (0.6–1.1) 
Cholesterol mg/dL 179 (158.25–205.25) 
Triglyceride mg/dL 134 (87.5–179.25) 
HDL mg/dL 45 (38–54) 
LDL mg/dL 104 (84–125) 
Prothrombin time INR 1.04 (1–1.1) 
Platelet ×10
9
/L 227 (189–279) 
Biopsy length cm 2.6 (2.4–3.0) 








F2  33 (28.4) 
F3  10 (8.6) 
F4  12 (10.3) 
Steatosis (%)   
0  27 (23.3) 
0–33  20 (17.2) 
33–66  33 (28.4) 
≥66  36 (31) 
Serum fibrosis indices 
  
AAR  0.92 (0.71–1.28) 
APRI  0.44 (0.29–0.76) 
FIB-4  1.39 (0.87–2.29) 
NFS  –1.46 (–2.57– –0.53) 
BARD   
0  14 (12.1) 
1  46 (39.7) 
2  44 (37.9) 
3  12 (10.3) 
4  0 
ARFI elastography   
Liver stiffness  m/s 1.13 (0.97–1.35) 




AAR, aspartate aminotransferase to alanine aminotransferase ratio; ALT, alanine 
aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; ARFI, 
acoustic radiation force impulse; AST, aspartate aminotransferase; BMI, body mass 
index; GGT, gamma-glutamyltranspeptidase; HDL, high-density lipoprotein; HOMA-
IR, homeostasis model assessment of insulin resistance; INR, international 
normalized ratio; IQR, interquartile range; LDL, low-density lipoprotein; NFS, 
NAFLD fibrosis score. 
 
Relationship between serum fibrosis indices and 
histological stages 
Figure 1 shows the changes in serum fibrosis indices across METAVIR stages. 
Positive linear correlations were reported both FIB-4 index and NFS 
according to METAVIR stages (P ≤ 0.001). However, the AAR and APRI 
were not significantly associated with histological stages. 
Moreover, the fasting insulin and glucose levels, and the HOMA-IR were also 
not significantly associated with histological stages (data not shown). 
 
Figure 1. Boxplots showing the changes in serum fibrosis indices (A, 
AAR; B, APRI; C, FIB-4; D, NFS) across METAVIR stages 
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Comparison of the diagnostic performances of serum 
fibrosis indices in predicting advanced fibrosis and 
cirrhosis 
Among the serum or mechanical fibrosis indicators, FIB-4 index and NFS 
showed greater diagnostic accuracy in terms of prediction of advanced 
fibrosis and cirrhosis. The corresponding AUROC curves were then analyzed 
to compare the diagnostic performances of the above indices for predicting 
advanced fibrosis (≥F3) and cirrhosis (F4) (Fig. 2). Figures 2A and B depict 
the AUROCs of the previously mentioned three indices for advanced fibrosis 
and cirrhosis. These indices were comparable for the diagnosis of ≥F3, 
although FIB-4 index and NFS exhibited significantly better performance than 
AAR or APRI (Table 5, P < 0.001). For ≥F3, an optimal cutoff FIB-4 index 
was 1.743, with 86.36% Se and 74.19% Sp. The AUROC for the FIB-4 index 
was 0.826 (95% CI, 0.737−0.915; P < 0.001) for predicting advanced fibrosis 
(Table 2, Fig. 2A). The corresponding AUROC for predicting advanced 
fibrosis was 0.824 (95% CI, 0.729−0.920; P < 0.001) for NFS (Table 3, Fig. 
2A).  
Similarly, FIB-4 index (AUROC, 0.874; 95% CI, 0.804−0.943; P < 0.001) 
exhibited better performance for predicting cirrhosis than NFS (Table 2 and 3, 
Fig. 2B). The corresponding AUROC for predicting cirrhosis was 0.869 (95% 
CI, 0.797−0.940; P < 0.001) for NFS (Table 3, Fig. 2B). The optimal cutoff 
FIB-4 index for predicting cirrhosis was 1.792, with 100.0% Se and 72.82% 





Table 2. Diagnostic accuracy of FIB-4 for the assessment of fibrosis 
according to METAVIR stages 
 
  AUROC 95% CI Cutoff Se (%) Sp (%) PPV (%) NPV (%) 
F0 vs. F1–4 0.851 0.750–0.952 1.057 69.09 100.00 100.00 12.82 
F0–1 vs. F2–4 0.684 0.585–0.783 1.733 56.36 80.00 72.09 66.67 
F0–2 vs. F3–4 0.826 0.737–0.915 1.743 86.36 74.19 44.19 95.83 
F0–3 vs. F4 0.874 0.804–0.943 1.792 100.00 72.82 30 100.00 
 
AUROC, area under the receiver operating characteristic; CI, confidence interval; NPV, 
negative predictive value; PPV, positive predictive value; Se, Sensitivity; Sp, Specificity. 
 
Table 3. Diagnostic accuracy of NFS for the assessment of fibrosis 
according to METAVIR stages 
 
  AUROC 95% CI Cutoff Se (%) Sp (%) PPV (%) NPV (%) 
F0 vs. F1–4 0.806 0.666–0.945 -1.915 65.45 100.00 100.00 11.63 
F0–1 vs. F2–4 0.709 0.613–0.805 -1.440 69.09 68.33 66.67 70.69 
F0–2 vs. F3–4 0.824 0.797–0.940 -0.780 77.27 80.65 48.57 93.75 
F0–3 vs. F4 0.869 0.729–0.920 -0.975 100 69.9 27.91 100.00 
 
AUROC, area under the receiver operating characteristic; CI, confidence interval; NFS, 
NAFLD fibrosis score; NPV, negative predictive value; PPV, positive predictive value; Se, 
Sensitivity; Sp, Specificity. 
 
Diagnostic performance of liver elastography according 
to histological staging 
Briefly, figure 3 shows the median value and 95% CI of LSM according to 
the METAVIR stages. The median LS measured by ARFI elastography 




elastography exhibited acceptable diagnostic performance for predicting 
advanced fibrosis and cirrhosis (Table 5, Fig. 2A and B). The AUROCs of 
LSM for predicting ≥F3 and F4 were 0.881 (95% CI, 0.800−0.962) and 0.828 
(95% CI, 0.845−1.000), respectively (Table 4). For ≥F3, the optimal cutoff LS 
value was 1.45 m/s, with 72.73% Se, 94.62% Sp, 76.19% PPV, and 93.62% 
NPV. The optimal cutoff value for predicting cirrhosis was 1.465 m/s, with 
91.67% Se, 90.29% Sp, 52.38% PPV, and 98.94% NPV (Table 4). 
Figure 2. Comparative AUROCs of AAR, APRI, FIB-4 index, NFS, 
and LSM by ARFI for the prediction of advanced fibrosis (A, ≥F3) and 





Figure 3. Distribution of liver stiffness measurements using ARFI 
elastography across METAVIR stages 
 
 
Table 4. Diagnostic accuracy of liver stiffness measurement using ARFI 
elastography for the assessment of fibrosis according to METAVIR 
stages 
 
  AUROC 95% CI Cutoff Se (%) Sp (%) PPV (%) NPV (%) 
F0 vs. F1–4 0.651 0.361-0.941 1.085 59.46 75 98.51 6.25 
F0–1 vs. F2–4 0.726 0.767–0.939 1.345 45.45 93.33 8621 65.12 
F0–2 vs. F3–4 0.881 0.763–0.916 1.450  72.23 94.62 76.19 93.62 
F0–3 vs. F4 0.926 0.740–0.916 1.465 91.67  90.29  52.38 98.94 
 
AUROC, area under the receiver operating characteristic; CI, confidence interval; NPV, 





Table 5. The pairwise comparisons of prediction performance of 




Parameter1 AUROC1 Parameter2 AUROC2 P-value 
≥ F3 vs. others 
AAR 0.652  
APRI 0.763  0.176  
FIB-4 0.826  0.001  
NFS 0.824  0.000  
ARFI 0.881  0.001  
APRI 0.763  
FIB-4 0.826  0.209  
NFS 0.824  0.353  
ARFI 0.881  0.045  
FIB-4 0.826  
NFS 0.824  0.953  
ARFI 0.881  0.232  
NFS 0.824  ARFI 0.881  0.276  
F4 vs. others 
AAR 0.652  
APRI 0.808  0.031  
FIB-4 0.874  0.000  
NFS 0.869  0.000  
ARFI 0.926  0.000  
APRI 0.808  
FIB-4 0.874  0.070  
NFS 0.869  0.300  
ARFI 0.926  0.011  
FIB-4 0.874  
NFS 0.869  0.859  
ARFI 0.926  0.198  
NFS 0.869  ARFI 0.926  0.280  
 
AAR, aspartate aminotransferase to alanine aminotransferase ratio; ALT, alanine 
aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; ARFI, acoustic 
radiation force impulse; AST, aspartate aminotransferase; AUROC, area under the receiver 
operating characteristic; NFS, NAFLD fibrosis score. 
 





As shown in figure 2 and table 5, the predictability of ARFI elastography for 
advanced fibrosis and cirrhosis was better than that of the FIB-4 index and 
NFS. To conduct pairwise comparisons between various indices’ 
performances, the DeLong’s test was performed and the results exhibited no 
statistical significance between ARFI elastography and other serum fibrosis 
indices (P > 0.05) (Table 5). As a result, we confirmed ARFI elastography as 
the best performing single noninvasive tool for the diagnosis of advanced 







In this prospective evaluation of 116 Korean patients with NAFLD, our study 
primarily found that noninvasive indices such as APRI, AAR, FIB-4 index, 
and LSM using ARFI elastography had comparable diagnostic performances 
for advanced fibrosis and cirrhosis in patients with NAFLD. The accurate 
evaluation of hepatic fibrosis is crucial for making decisions regarding 
treatment and for predicting clinical outcomes in patients with NAFLD.
5, 28 
To 
date, liver biopsy, has been a standard method for assessing hepatic fibrosis. 
Recently, several noninvasive methods for the replacement of liver biopsy 




A number of serum fibrosis indices have been proposed as alternatives to liver 
biopsy, especially for patients with viral hepatitis. These ranged from a simple 
test, such as platelet count measurement, to more complicated tests, including 






22-25, 30, 31 
Although these tests have been 
validated in several clinical studies, their clinical performances compared to 
liver biopsy is debatable.
32-34
 In the current study, we evaluated and compared 
the diagnostic accuracies of various serum fibrosis indices in patients with 
NAFLD who underwent liver biopsy. Our results also showed strong, positive 
correlations between serum fibrosis indices and histological fibrosis stages.  
NASH is related with metabolic syndrome and glucose tolerance 
abnormalities.
35, 36




abnormalities, are included in NFS formula.
26
 In the current study, FIB-4 
index and NFS showed good diagnostic accuracy for predicting advanced 
fibrosis and cirrhosis. FIB-4 index is known as a simple, accurate, and 
inexpensive method for assessing hepatic fibrosis in patients with hepatitis 
C.
37
 However, FIB-4 index does not include metabolic factors for calculation. 
Therefore, this finding may indicate strong relations between metabolic 
factors and the progression of liver fibrosis as indicated by Takahashi et al.
38
  
In the previous study, the cutoff FIB-4 index for predicting advanced fibrosis 
was 3.25.
23
 In our study, the cutoff FIB-4 index was 1.738 and its AUROC 
was 0.825. The different results between the two studies are attributable to the 
different disease etiologies for each group of patients. Our study included 
patients with NAFLD, whereas patients in the previous study had chronic 
hepatitis C. Therefore, it revealed FIB-4 index measurement as a useful 
noninvasive method for assessing advanced fibrosis and cirrhosis not only in 
patients with chronic hepatitis C but also in patients with NAFLD. 
The NFS has been reported to have an excellent diagnostic accuracy for 
advanced fibrosis in patients with NAFLD. In this respect, Calès et al. 
reported an AUROC of 0.932 for NFS in the detection of severe fibrosis.
39
 
NFS had an acceptable accuracy for the diagnosis of advanced fibrosis using 
liver biopsy, although our data revealed a smaller AUROC for the NFS of 
0.823 in the diagnostic performance of advanced fibrosis. 
One of the most widely used noninvasive methods to predict hepatic fibrosis 
is TE-based LSM. TE is easy to use can be kept on hand in the bedside or 






recent meta-analysis demonstrated that TE was more suitable for the diagnosis 
of advanced fibrosis or cirrhosis than for mild fibrosis.
41
 However, its 
accuracy might be dependent on various factors such as the acquisition rate of 
an adequate specimen, BMI, technical consistency, and the histological 
grading of fibrosis.
42
 In addition, the technical drawbacks of TE can limit its 
use in obese patients with excessive subcutaneous fat or in cirrhotic patients 
with massive ascites.
43 
ARFI elastography is a new imaging technique that 
could overcome the above technical drawbacks, and it has been recently 
investigated in the assessment of hepatic fibrosis.
17-18, 44,45 
Previous studies have shown a positive correlation between LSM by ARFI 
elastography and fibrosis stage in patients with hepatitis C.
44
 However, the 
diagnostic performance of ARFI elastography has not been studied in patients 
with NAFLD. In the current study, LS measured by ARFI elastography, 
gradually increased in parallel with the METAVIR fibrosis stage. Moreover, 
ARFI elastography exhibited the highest diagnostic performance for advanced 
fibrosis and cirrhosis that was comparable to that of the FIB-4 index and NFS. 
The cutoff value (1.345 m/s) for the prediction of significant fibrosis (≥F2) 
was similar to the value (1.34 m/s) reported in a previous meta-analysis.
46
 
However, the cutoff value (1.45 m/s) for the detection of advanced fibrosis 
(≥F3) in the current study was lower than the value proposed in the meta-
analysis (1.55 m/s).
46
 In our study, the proportions of patients with advanced 
fibrosis and cirrhosis were different compared to those in the meta-analysis 
(18.9% vs. 40%).
46 
Therefore, this discrepancy accounts for the different 




This study had several limitations. First, our study utilized a cross-sectional 
design. Second, we did not evaluate for risk factors that might have affected 
the discordant results between the histological data and the noninvasive 
fibrosis assessment. Additional statistical analyses are required to identify the 
risk factors that could interfere with concordance. Third, there are other 
potential panels for the evaluation of liver fibrosis including the FibroTest

, 
and the European liver fibrosis panel, which were not examined in this 
study.
47, 48
 Fourth, although our study population was homogenous, our results 
are not readily applicable to the general population given the limited sample 
size and the spectrum or referral bias. More generalizable results could be 
obtained from a larger-scale study. 
In conclusion, with these caveats in mind, LSM by ARFI was an excellent 
imaging method for confirming advanced fibrosis and cirrhosis in patients 
with NAFLD. In addition, FIB-4 index and NFS were reliable markers for the 
assessment of advanced fibrosis and cirrhosis. Further prospective, 
longitudinal studies are needed to determine whether noninvasive fibrosis 
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서론: 비알코올 지방간 환자에서 비침습적 섬유화 측정 방법이 간 
조직검사를 대신할 수 있다는 것은 현재까지 논란의 여지가 있다. 
본 연구는 비알코올 지방간 환자에서 진행된 섬유화 혹은 간 경변
을 예측하기 위한 비침습적 섬유화 방법의 진단 예측 능력을 평가
하고자 한다.  
방법: 2013 년 3 월부터 2014 년 9 월까지 치료를 받지 않은, 116
명의 비알코올 지방간 환자를 전향적으로 등록하였다. ARFI 초음파
를 이용하여 간 탄력도를 측정하였고, 동시에 조직 검사를 시행하였
다. AUROC 커브를 분석하여 진행성 섬유화와 간 경변을 예측하기 
위한 혈액학적 검사와 ARFI 초음파의 진단능을 비교하였다. 
결과: 환자의 중위 연령은 54.3 세 (범위 1878)였다. FIB-4 
index, NFS, BARD score, ARFI 초음파를 이용한 간탄력도는 
Metavir 병기에 따라 모두 강한 양의 관계를 보여 주었다. 진행성 
섬유화와 간경변 예측에서 ARFI 초음파를 이용한 간 탄력도가 가
장 높은 AUROC 를 보여주었으며 이 외에도 FIB-4 index 와 NFS
가 높은 AUROC 를 보여주었다. 
결론: ARFI 초음파는 비알코올 지방간 환자에서 진행된 섬유화와 




index 와 NFS 도 비알코올 지방간 환자의 간 섬유화를 측정하는데 
있어 진단적으로 유용하다. 
------------------------------------- 
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